Cerus Corporation (CERS)vsEdwards Lifesciences Corp (EW)
CERS
Cerus Corporation
$1.77
-2.75%
HEALTHCARE · Cap: $330.54M
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 2844% more annual revenue ($6.07B vs $206.13M). EW leads profitability with a 17.7% profit margin vs -7.6%. EW earns a higher WallStSmart Score of 55/100 (C).
CERS
Avoid32
out of 100
Grade: F
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CERS.
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Strong operational efficiency at 23.7%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -25.7% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : CERS
Revenue growth of 13.7% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bear Case : CERS
The primary concerns for CERS are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Key Dynamics to Monitor
CERS profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.
CERS carries more volatility with a beta of 1.53 — expect wider price swings.
CERS is growing revenue faster at 13.7% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 32/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cerus Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?